Abstract
1. The plasma concentrations and urinary excretion of nedocromil sodium have been determined following single dose administration in six healthy volunteers dosed orally (1 mg kg-1) and intravenously (0.2 microgram kg-1 for 30 min). Similar parameters were measured in six volunteers and twelve asthmatic patients dosed by inhalation (4 mg). Multiple dose kinetic measurements were also made. 2. The intravenous data demonstrated that nedocromil sodium is a high clearance drug (10.2 +/- 1.3 ml min-1 kg-1). The data were fitted by a two compartment model with very rapid elimination from the central compartment (k10 = 0.088 +/- 0.021 min-1; beta = 0.013 +/- 0.002 min-1). 81% of the dose was excreted in the urine. 3. Oral absorption was low (2-3% of the dose) and contributed negligibly to the plasma profile after inhalation. 4. After inhalation of single doses of 4 mg in volunteers and patients plasma concentration rose rapidly, plateaued and then fell monoexponentially with a half-life of approximately 2 h. The data fitted a 'flip-flop' model with two absorption components. The extent of absorption was up to 6% of the dose with less in patients. 5. After multiple dosing with 4 mg four times daily for 7 days in volunteers negligible accumulation was observed. The pattern was similar in patients treated with 4 mg four times daily after 1, 6 and 12 months.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Auty R. M. The clinical development of a new agent for the treatment of airway inflammation, nedocromil sodium (Tilade). Eur J Respir Dis Suppl. 1986;147:120–131. [PubMed] [Google Scholar]
- Clark B., Neale M. G. Hepatic and renal clearance of sodium cromoglycate. J Pharm Pharmacol. 1981 Nov;33(11):744–745. doi: 10.1111/j.2042-7158.1981.tb13922.x. [DOI] [PubMed] [Google Scholar]
- Eady R. P., Greenwood B., Jackson D. M., Orr T. S., Wells E. The effect of nedocromil sodium and sodium cromoglycate on antigen-induced bronchoconstriction in the Ascaris-sensitive monkey. Br J Pharmacol. 1985 Jun;85(2):323–325. doi: 10.1111/j.1476-5381.1985.tb08864.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lal S., Malhotra S., Gribben D., Hodder D. An open assessment study of the acceptability, tolerability and safety of nedocromil sodium in long-term clinical use in patients with perennial asthma. Eur J Respir Dis Suppl. 1986;147:136–142. [PubMed] [Google Scholar]
- Lal S., Malhotra S., Gribben D., Hodder D. Nedocromil sodium: a new drug for the management of bronchial asthma. Thorax. 1984 Nov;39(11):809–812. doi: 10.1136/thx.39.11.809. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Neale M. G., Brown K., Hodder R. W., Auty R. M. The pharmacokinetics of sodium cromoglycate in man after intravenous and inhalation administration. Br J Clin Pharmacol. 1986 Oct;22(4):373–382. doi: 10.1111/j.1365-2125.1986.tb02905.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Newman S. P., Pavia D., Morén F., Sheahan N. F., Clarke S. W. Deposition of pressurised aerosols in the human respiratory tract. Thorax. 1981 Jan;36(1):52–55. doi: 10.1136/thx.36.1.52. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Roberts J. A., Thomson N. C. Attenuation of exercise-induced asthma by pretreatment with nedocromil sodium and minocromil. Clin Allergy. 1985 Jul;15(4):377–381. doi: 10.1111/j.1365-2222.1985.tb03006.x. [DOI] [PubMed] [Google Scholar]
- Shaw R. J., Kay A. B. Nedocromil, a mucosal and connective tissue mast cell stabilizer, inhibits exercise-induced asthma. Br J Dis Chest. 1985 Oct;79(4):385–389. doi: 10.1016/0007-0971(85)90073-7. [DOI] [PubMed] [Google Scholar]
- Wagner J. G. Pharmacokinetics and bioavailability. Triangle. 1975;14(3-4):101–108. [PubMed] [Google Scholar]
- Youngchaiyud P., Lee T. B. Effect of nedocromil sodium on the immediate response to antigen challenge in asthmatic patients. Clin Allergy. 1986 Mar;16(2):129–134. doi: 10.1111/j.1365-2222.1986.tb00756.x. [DOI] [PubMed] [Google Scholar]